Skip to main content
Clinical Trials/NCT06218901
NCT06218901
Recruiting
Not Applicable

the Association of Psychological Distress in Patients With Advanced Lung Cancer Treated With Immunotherapy or Targeted Therapy

Shanghai Chest Hospital1 site in 1 country500 target enrollmentJanuary 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Neoplasms
Sponsor
Shanghai Chest Hospital
Enrollment
500
Locations
1
Primary Endpoint
Objective response rate (ORR)
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment. Psychological distress is common and affects the efficacy and prognosis of patients with lung cancer. The systematic anti-tumor therapy may effectively relieve psychological distress including anxiety, depression, and fatigue in patients with advanced lung cancer, the relief of the psychological distress can in turn improve the therapeutic effect.

In summary, this study is to explore the associations of (dynamic) psychological stress with the efficacy and survival of anti-tumor therapy including immunotherapy and targeted therapy for advanced lung cancer patients.

Registry
clinicaltrials.gov
Start Date
January 1, 2016
End Date
December 31, 2028
Last Updated
11 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Xiaomin Niu

Principal Investigator

Shanghai Chest Hospital

Eligibility Criteria

Inclusion Criteria

  • Histologically proven diagnosis of lung cancer
  • 18 years of age or older
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

  • Not willing to participate in this clinical trial

Outcomes

Primary Outcomes

Objective response rate (ORR)

Time Frame: 20 years

Collect detailed clinical information on patients with SCLC via the electronic medical records

Disease control rate (DCR)

Time Frame: 20 years

Collect detailed clinical information on patients with SCLC via the electronic medical records

Progression-free survival (PFS)

Time Frame: 20 years

Collect detailed clinical information on patients with SCLC via the electronic medical records

Secondary Outcomes

  • Overall survival (OS)(20 years)

Study Sites (1)

Loading locations...

Similar Trials